PUBLISHER: Polaris Market Research | PRODUCT CODE: 1762319
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1762319
The global molecular diagnostics for sexually transmitted diseases market size is expected to reach USD 7.85 billion by 2034, according to a new study by Polaris Market Research. The report "Molecular Diagnostics for Sexually Transmitted Diseases Market Size, Share, Trends, & Industry Analysis Report By Product (Instruments & Services, Consumables, and Software), By Application, By Technology, By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Molecular diagnostics for sexually transmitted diseases (STDs) involves advanced laboratory techniques that pinpoint the genetic material, such as DNA or RNA, of the microorganisms causing these infections. Unlike older methods that might look for antibodies or grown cultures, molecular tests directly identify the pathogen itself. This allows for highly accurate and sensitive detection, often enabling diagnosis even in the early stages of an infection or when symptoms are not yet present, which is crucial for timely treatment and preventing further spread.
The market for molecular diagnostics for STDs is experiencing significant growth due to the rising global incidence of STDs, which necessitates more effective and rapid diagnostic solutions to manage public health challenges. Additionally, ongoing technological advancements in molecular testing, including the development of multiplex assays that can detect multiple pathogens simultaneously, are enhancing testing efficiency and accessibility. The increasing awareness among healthcare professionals and the general public about the importance of early and accurate STD diagnosis also contributes to the expanding adoption of these advanced diagnostic methods.
By product, the consumables segment, encompassing reagents and kits, holds the largest share due to its essential role in every molecular STD test.
Based on application, the CT/NG testing segment dominated in 2024 as these are among the most prevalent STDs worldwide.
In terms of technology, the laboratory testing segment held the largest share in 2024, supported by the established infrastructure of centralized labs.
By region, North America dominated the molecular diagnostics for sexually transmitted diseases market revenue share in 2024. Asia Pacific is projected to witness the fastest growth during the forecast period.
A few key players in the market include Abbott Laboratories; F. Hoffmann-La Roche AG (Roche Diagnostics); bioMerieux SA; QIAGEN N.V.; Hologic Inc.; Becton, Dickinson and Company (BD); Siemens Healthineers AG; DiaSorin S.p.A.; Thermo Fisher Scientific Inc.; QuidelOrtho Corporation; and Seegene Inc.
Polaris Market Research has segmented the molecular diagnostics for sexually transmitted diseases market report on the basis of product, application, technology, and region:
By Product Outlook (Revenue - USD Billion, 2020-2034)
Instruments & Services
Consumables
Software
By Application Outlook (Revenue - USD Billion, 2020-2034)
CT/NG Testing
Syphilis Testing
Gonorrhea Testing
HSV Testing
HPV Testing
HIV Testing
Trichomonas
Ureaplasma + Mycoplasma
Others
By Technology Outlook (Revenue - USD Billion, 2020-2034)
Laboratory Testing
Commercial/Private Labs
Public Health Labs
PoC testing
By Regional Outlook (Revenue - USD Billion, 2020-2034)
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America